New York University

Kevin Drew

Paramjit S Arora

Richard Bonneau

Brooke Bullock Lao

Danielle Guarracino

The present invention relates to oxopiperazines that mimic helix &#x3b1;B of the C-terminal transactivation domain of HIF1&#x3b1;. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1&#x3b1; with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression

The present invention relates to oligooxopiperazines for modulating the p53-Mdm2 interaction. Exemplary oligooxopiperazines include those of Formula IA, Formula IB, and Formula IC below (wherein the various substituents are as defined herein). Methods of using the oligooxopiperazines are also disclosed. 

Oxopiperazine helix mimetics as inhibitors of the p53-MDM2 interaction

The present invention relates to oxopiperazines that mimic helix &#x3b1;B of the C-terminal transactivation domain of HIF1&#x3b1;. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1a with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

Growing community of inventors

Austin, TX, United States of America

Kevin Drew